Changing public opinion and regulations in recent years have led to an unprecedented growth in the market for cannabinoid-based products. As the prevalence of cannabinoids such as CBD increases, the pharmaceutical industry has only just begun to explore their therapeutic value.  

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. Cannabinoids are being explored as a treatment for several indications. However, formulating effective pharmaceutical products with CBD and other cannabinoids introduces scientific, regulatory, and even legal challenges.

This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including:

  • The history of medicinal cannabis
  • An overview of global pharmaceutical cannabinoid usage today
  • Common challenges formulating with CBD and other cannabinoids
  • A deep dive into cannabinoid formulation and stability-enhancement techniques
  • How to navigate the volatile regulatory and legal landscape surrounding cannabinoid-based drug products

Anyone who has interest in developing a cannabinoid-based pharmaceutical product will benefit from this webinar. Join experts from Lubrizol Life Science Health as they help you navigate this exciting, new frontier in pharma.

Featured Speakers

Dr. Andrew Loxley, BSc, PhD

International Formulation Development Consultant
Lubrizol Life Science Health - CDMO Division

Andrew Loxley, BSc, PhD, is a product and business development leader, materials, formulation and process innovations expert, and serial entrepreneur. Working with boards and executive management of companies spanning early stage to mature multinational, Dr. Loxley has contributed to the technical and commercial successes of household-name products and licensed pharmaceuticals, and has helped to build global businesses. Dr. Loxley headed formulation development at the Lubrizol Life Science Health – CDMO Division, and is the co-founder of Cannavail, SA, developing, manufacturing and distributing cannabis-derived health-care products.

Judith Cohen

Vice President, Quality Assurance
Lubrizol Life Science Health - CDMO Division

Judith Cohen joined Lubrizol Life Science Health – CDMO Division (LLS Health) in 2013 as Associate Director, Quality Assurance. Prior to joining LLS Health, Judith held leadership roles for over 22 years at Johnson & Johnson within the Pharmaceutical and Medical Device Sectors. She has extensive experience developing and implementing quality systems to support the manufacture and analytical characterization of clinical trial materials and commercial products. Judith has been integral in the preparation of Chemistry & Manufacturing Control sections for regulatory submissions worldwide for both pharmaceutical and drug/device combination products leading to the commercialization of over 20 products. Judith earned her Bachelor of Science in Chemistry from the University of Delaware and is a Fellow of the American Chemical Society.

NOW AVAILABLE ON-DEMAND

Register now for this webinar